Description

BeOne Medicines Is Not Just A BRUKINSA Story — Its Oncology Pipeline Is Expanding!

BeOne Medicines reported strong financial and operational results for the second quarter of 2026, demonstrating growth across its commercial portfolio alongside significant pipeline advancements. Total revenues increased by 30% year-over-year to $1.7 billion, driven primarily by BRUKINSA, their flagship BTK inhibitor, which achieved over $1.2 billion in global sales—a 31% increase compared to the prior year. Notably, BRUKINSA maintained market leadership in both the U.S. and globally and expanded its use across five approved B-cell malignancy indications. The company reported the highest sustained new patient starts for BRUKINSA since its launch, with favorable early trends in therapy duration and patient adherence, partly attributed to a recently introduced tablet formulation. However, the duration of therapy data remain immature, and competition, including from acalabrutinib-venetoclax regimens, remains present though with no significant impact observed so far.